Want to see JP:4591 full AI Analyst Report?
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥57.00 - ¥120.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)477.44K
Market Cap
¥4.98B
Enterprise Value¥610.54
Total Cash (Recent Filing)¥2.83B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.08
Shares Outstanding56,572,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)1.54
Price to Sales (P/S)1456.29
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetZero debt and net cash reduce insolvency and refinancing risk, giving Ribomic greater flexibility to fund research and operations without immediate lender constraints.
Meaningful Equity BaseA meaningful equity base provides some capacity to absorb continued development losses and support operations, although its durability depends on whether future cash burn can be reduced.
Revenue ReboundThe latest revenue rebound indicates some recovery in commercial activity from a very low base. Sustained growth could improve operating leverage, though current sales remain small relative to expenses.
Bears Say
Persistent Deep LossesPersistent deep losses show that Ribomic has not yet established a commercially self-sustaining model. Continued deficits can limit strategic flexibility and increase dependence on external capital.
Structural Cash BurnConsistently negative operating and free cash flow means operations consume cash rather than fund themselves. This can steadily reduce available resources and create future financing requirements.
Eroding Capital BaseDeclining equity indicates that accumulated losses are eroding the capital base despite the current net-cash position. If this continues, financial resilience and funding capacity will weaken over time.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥57.00 and its highest was ¥120.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥4.98B.
When is Ribomic, Inc.’s upcoming earnings report date?
Ribomic, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 80 days.
How were Ribomic, Inc.’s earnings last quarter?
Ribomic, Inc. released its earnings results on Aug 13, 2026. The company reported -¥4.87 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 56,572,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Ribomic, Inc. reported an EPS of -¥4.87 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.299%.
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.